BioPharma Drug Discovery
Everest Medicines Secures Exclusive Asia Pacific Rights To First In Class Dual Target SHPT Therapy MT1013
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturi...
February 06, 2026 | News
Biosion Doses First Patient In Phase 1 Trial Of Novel Anti SIRPα Antibody BSI 082
Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's "In...
February 05, 2026 | News
Insilico Medicine Receives $5 Million Milestone From Menarini Group After First Patient Dosed In Phase 1 Trial Of AI Designed Cancer Therapy
Followed by the development and regulatory milestone payment of USD 3 million in July 2025, Insilico received an additional milestone paymen...
February 05, 2026 | News
SanegeneBio Licenses RNAi Programme To Genentech In Global Deal Valued Up To USD 1.7 Billion
SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech - SanegeneBio to receive $200 million up...
February 04, 2026 | News
Ascletis Pharma Reports Positive Phase III Safety Results For Denifanstat In Moderate To Severe Acne
Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label ...
February 03, 2026 | News
MicuRx Pharmaceuticals Receives FDA IND Clearance For MRX 5 In Mycobacterium abscessus Pulmonary Disease
MicuRx Pharmaceuticals, Inc. ("MicuRx"), a clinical-stage biopharmaceutical company focused on developing novel anti-infective therapies for drug-resistant...
February 03, 2026 | News
Closing Asia’s Cancer Evidence Gap Through Translational Science And Policy Leadership
In this BioPharma APAC interview, Dr Yun Yen, Program Committee Chair for the 2026 ASCO Breakthrough meeting, shares a candid translational...
February 02, 2026 | Expert Insight
Kazia Therapeutics Advances First In Class Nuclear PD L1 Protein Degrader With Compelling Preclinical Evidence
Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, announced co...
February 02, 2026 | News
Insilico Medicine Partners With Qilu Pharmaceutical Group To Advance AI Driven Cardiometabolic Drug Discovery
Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, and Qilu Pharmaceutical Group, a major comprehensive modern pharmaceuti...
January 29, 2026 | News
Hanmi Pharmaceutical Advances Global GLP 1 Strategy With Mexico Distribution Agreement For Efpeglenatide
Hanmi is accelerating its global market entry with efpeglenatide, Korea's first domestically developed GLP-1 class obesity and metabolic disease ...
January 29, 2026 | News
Nuance Pharma’s Ohtuvayre NDA Accepted For Review In China For COPD Maintenance Treatment
Nuance Pharma announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA)...
January 28, 2026 | News
China Approves First Ever Therapy For Chronic Hepatitis D With Conditional Clearance For Libevitug
Huahui Health announced that China's National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for chroni...
January 28, 2026 | News
Innovent’s Tri Specific Antibody IBI3003 Secures US FDA Fast Track Designation In Relapsed Or Refractory Multiple Myeloma
Innovent Biologics, Inc. , a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment...
January 28, 2026 | Report
Merz Therapeutics Submits XEOMIN For Paediatric Spasticity Indication Across Europe
Merz Therapeutics, a leading player in neurology-focused specialty pharma, announced that it has completed the regulatory submission for XEOMIN®&...
January 27, 2026 | News
Most Read
- Innovations In Magnetic Resonance Imaging Introduced By United Imaging
- Management of Relapsed/Refractory Multiple Myeloma
- 2025 Drug Approvals, Decoded: What Every Biopharma Leader Needs to Know
- BioPharma Manufacturing Resilience: Lessons From Capacity Expansion and Supply Chain Resets from 2025
- APAC Biopharma Review 2025: Innovation, Investment, and Influence on the Global Stage
- Top 25 Biotech Innovations Redefining Health And Planet In 2025
- How Health Systems Are Reshaping Drug Adoption, Partner Models, and Market Access in 2026
- The New AI Gold Rush: Western Pharma’s Billion-Dollar Bet on Chinese Biotech
- Single-Use Systems Are Rewiring Biopharma Manufacturing
- The State of Biotech and Life Science Jobs in Asia Pacific – 2025
- Asia-Pacific Leads the Charge: Latest Global BioSupplier Technologies of 2025
- Invisible Threats, Visible Risks: How the Nitrosamine Crisis Reshaped Asia’s Pharmaceutical Quality Landscape
Bio Jobs
- Sanofi Turns The Page As Belén Garijo Steps In And Paul Hudson Steps Out
- Global Survey Reveals Nearly 40% of Employees Facing Fertility Challenges Consider Leaving Their Jobs
- BioMed X and AbbVie Begin Global Search for Bold Neuroscience Talent To Decode the Biology of Anhedonia
- Thermo Fisher Expands Bengaluru R&D Centre to Advance Antibody Innovation and Strengthen India’s Life Sciences Ecosystem
- Accord Plasma (Intas Group) Acquires Prothya Biosolutions to Expand Global Plasma Capabilities
- ACG Announces $200 Million Investment to Establish First U.S. Capsule Manufacturing Facility in Atlanta
- AstraZeneca Invests $4.5 Billion to Build Advanced Manufacturing Facility in Virginia, Expanding U.S. Medicine Production
News
